The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback